secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2026-09-22T20:15:34+00:00
Accession:  0001104659-26-109639
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Fast Track to Quoin's QRX003 for Peeling Skin Syndrome
-----------------------------------------------------------------

- FDA granted Fast Track Designation to QRX003 for Peeling Skin Syndrome (PSS) on Sept 22, 2026.
- First-ever Fast Track for a PSS therapy; second Fast Track for QRX003 (prior: Netherton Syndrome).
- Follows July 2026 FDA clearance of first-ever IND for PSS; Phase 2/3 study planned 2H 2026.
- Phase 2/3 to enroll up to 12 pediatric/adult patients; targeting 2028 approval; no approved PSS treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926109639/0001104659-26-109639-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926109639/tm2625948d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-109639

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer